WALTHAM, Mass. — Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, expanding the company’s global capabilities for pharmaceutical and biotechnology customers.
The Waltham-based company said the new facility, located within GoCo Health Innovation City, is designed to support drug development programs from preclinical studies through post-approval work. The laboratory offers bioanalytical and biomarker services for customers developing both small molecules and more complex therapies.
The facility includes Good Laboratory Practice capabilities and technology for cell-based assays, immunochemistry, liquid chromatography-mass spectrometry, molecular genomics, flow cytometry and proteomics. Thermo Fisher said the lab will support work involving peptides, antibodies, oligonucleotides, and cell and gene therapies.
“Our new Gothenburg laboratory is purpose-built to address the evolving needs of modern drug development, particularly as therapies become more complex and data requirements increase,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific. “By investing in advanced capabilities and strategic locations, such as Gothenburg, we are helping our customers in Europe and globally accelerate innovation and bring new therapies to patients faster.”
The new laboratory is part of Thermo Fisher’s PPD clinical research business, which provides laboratory services for clinical trials. PPD Laboratory Services includes bioanalytical, biomarker, GMP, vaccine sciences and central lab operations intended to support clinical trial and drug development programs.
Thermo Fisher said the Gothenburg site complements its existing bioanalytical laboratories in Richmond, Virginia, and Suzhou, China. The company said the expansion also reinforces its long-term commitment to Sweden’s life sciences sector and its growth as an employer and investor in the region.
